Defunct Company
Total Trials
7
As Lead Sponsor
3
As Collaborator
4
Total Enrollment
678
NCT01328236
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2010
Completion: Sep 30, 2015
NCT01408602
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
Role: Collaborator
Start: Nov 30, 2011
Completion: Jul 31, 2014
NCT02973893
Study of VF001-DP in Patients With Chronic Venous Leg Ulcers
Start: Nov 30, 2016
Completion: Feb 28, 2019
NCT03487549
Cantharidin and Occlusion in Verruca Epithelium
Start: Mar 27, 2018
Completion: Jul 15, 2019
NCT04514406
APERTO CVS PMCF Study
Phase: N/A
Start: Jan 25, 2021
Completion: Dec 1, 2023
NCT06321770
Oral Supplementation With Active Collagen Peptides and Skin Health Improvement
Start: Mar 1, 2024
Completion: Jun 3, 2024
NCT06448585
Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.
Phase: Phase 4
Start: May 29, 2024
Completion: Dec 10, 2024